Research programme: Six1/Eya2 complex inhibitors - SixOne Solutions
Latest Information Update: 20 Jul 2016
At a glance
- Originator SixOne Solutions
- Class Antineoplastics; Small molecules
- Mechanism of Action Homeodomain protein inhibitors; Nuclear protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 20 Jul 2016 Preclinical trials in Breast cancer in USA (unspecified route)